

NEW YORK, Sept. 16, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

**[Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth](http://www.reportlinker.com/p01623519/Multiple-Sclerosis-Therapeutics-to-2019---Treatment-Diversification-Increasing-Efficacy-and-Pipeline-Innovation-Combine-to-Drive-Growth.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology)** [http://www.reportlinker.com/p01623519/Multiple-Sclerosis-Therapeutics-to-2019---Treatment-Diversification-Increasing-Efficacy-and-Pipeline-Innovation-Combine-to-Drive-Growth.html#utm\\_source=prnewswire&utm\\_medium=pr&utm\\_campaign=Pathology](http://www.reportlinker.com/p01623519/Multiple-Sclerosis-Therapeutics-to-2019---Treatment-Diversification-Increasing-Efficacy-and-Pipeline-Innovation-Combine-to-Drive-Growth.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology)

*Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth*

## Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth". Currently there are a number of disease-modifying drugs in the Multiple Sclerosis (MS) market that are indicated for the treatment of relapsing forms of the disease, specifically reducing the frequency of disease relapses. The market is led by Copaxone, which achieved global sales of \$4 billion in 2012. Over the forecast period 2012–2019, a variety of new drugs are due to enter the market that will offer a vast improvement in efficacy but also convenience, as many of these drugs are orally administered. Additionally, a high number of monoclonal Antibodies (mAbs) are due to enter the market and diversify it in terms of its portfolio for late stage or aggressive MS. All of these drugs have been shown to offer substantial improvements over current therapies. The price of these new therapies is expected to be high, particularly for the mAbs, but this is unlikely to hinder their uptake. As a result of this, as well as an overall increase in the treated population, GBI

Research believes the global market has the potential to grow to a value of \$17.9 billion by 2019.

## Scope

- A brief introduction to MS, including the disease's history, pathogenesis, risk factors and diagnosis.- In-depth analysis of the eight major disease-modifying drugs for MS, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map comparing the drugs in terms of safety and efficacy.- Comprehensive review of the pipeline for MS therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market in the forecast period. The pipeline is analyzed on the basis of phase distribution, molecule types and molecular targets, as well as administration routes.- Additional analysis of pipeline drug clinical trials by phase, molecule type, trial size and trial duration.- Multi-scenario forecast model of the market, taking into account how it will be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology.- Discussion of the drivers and barriers for market growth or decay.

## Reasons to buy

- Understand the different levels of MS therapies, from early-stage/mild MS to late-stage/aggressive MS.- Understand the vast scope of the pipeline, including which molecule types and mechanisms of action are prominent.- Observe the trends in clinical trial duration and size amongst clinical phases and molecule types, and use the clinical trial failure rate analysis to assess the risk profiles of current and/or future developmental programs for multiple sclerosis therapeutics.- Observe the shift in clinical trial endpoints with clinical phase, and use this data to potentially influence any future developmental programs. - Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the multiple sclerosis therapeutics market.

## 1 Table of Contents

1.1 List of Tables 71.2 List of Figures 72 Introduction 82.1 Disease Overview 82.2 Epidemiology 82.3 Symptoms 92.4 Etiology 92.5 Pathophysiology 102.5.1 Blood Brain Barrier Degradation

102.5.2 Cellular Infiltration of the Central Nervous System 102.6 Co-morbidities/Complications 112.7 Diagnosis 122.7.1 McDonald Criteria 122.7.2 Physical Examination 132.7.3 MRI Scans 132.7.4 Lumbar Puncture 132.7.5 Other Diagnostic Tests 132.8 Prognosis 142.9 Treatment Efficacy 152.10 Treatment Options 152.10.1 Corticosteroids 162.10.2 Anti-neoplastic Drugs 162.10.3 Skeletal Muscle Relaxants 162.10.4 Pain Management in MS 172.11 Treatment Algorithm 172.12 Non-pharmacological Therapies 193 Therapeutic Landscape 203.1 Copaxone (glatiramer acetate) – Teva Pharmaceuticals 203.2 Betaseron (interferon beta 1b) – Bayer AG 213.3 Avonex (interferon beta 1a IM) – Biogen 223.4 Rebif (interferon beta 1a SC) – Merck Serono 233.5 Tysabri (natalizumab) – Biogen Idec/Elan Corporation 243.6 Gilenya (fingolimod hydrochloride) – Mitsubishi Tanabe and Novartis 253.7 Aubagio (Teriflunomide) – Genzyme Corporation and Sanofi-Aventis 263.8 Novantrone (mitoxantrone) – Merck Serono 263.9 Conclusion 283.10 Unmet Need 284 Pipeline for Multiple Sclerosis Therapeutics 294.1 Overall Pipeline 294.2 Route of Administration 314.3 Molecular Targets within the MS Pipeline 324.4 Clinical Trials 344.4.1 Failure Rate of Developmental Programs 34

4.4.2 Clinical Trial Size 364.4.3 Clinical Trial Duration 384.5 Promising Pipeline Candidates 404.5.1 Lemtrada (alemtuzumab) – Genzyme and Bayer Schering Pharma 404.5.2 Tecfidera (dimethyl fumarate) – Biogen Idec 404.5.3 Laquinimod (laquinimod sodium) – Teva Pharmaceuticals 414.5.4 ocrelizumab – F. Hoffman-La Roche 424.5.5 daclizumab – Biogen Idec and Abbot Laboratories 424.5.6 finategrast – GlaxoSmithKline 434.5.7 Siponimod (BAF-312) – Novartis AG 444.6 Conclusion 445 Market Forecast to 2019 475.1 Geographical Markets 475.1.1 Key Developed Markets 475.1.2 US 505.1.3 Top Five EU Countries 525.1.4 Japan 565.2 Drivers and Barriers 585.2.1 Drivers 585.2.2 Barriers 596 Deals and Strategic Consolidations 616.1 Major Co-development Deals 616.1.1 Daiichi Sankyo Enters into an Agreement with Amplimmune 636.1.2 Karo Bio Enters into an Agreement with Pfizer 636.1.3 Proteostasis Enters into an Agreement with Elan 636.1.4 Lycera Enters into an Agreement with Merck 646.1.5 Facet Enters into an Agreement with Trubion 646.1.6 UCB Enters into an Agreement with Biogen 646.2 Major Licensing Deals 656.2.1 Addex Extends its Licensing Agreement with Merck 686.2.2 Biogen Enters into a Licensing Agreement with Acorda Therapeutics 696.2.3 Genzyme Enters into a Licensing Agreement with Bayer Healthcare 696.2.4 Novartis Enters into a Licensing Agreement with Peptimmune 696.2.5 Merck Serono Enters into a Licensing Agreement with Apitope Technology 696.2.6 Antisense Enters into a Licensing Agreement with Teva Pharmaceutical 706.2.7 BioMS Medical Corp Enters into a Licensing Agreement with Eli Lilly 706.2.8 Biotica Enters into an Agreement with Wyeth 707 Appendix 717.1 Pipeline Product Tables by Phase 717.2 Market Forecasting Data Tables to 2019 817.3 Market Definition 857.4 Abbreviations 857.5 References 867.6 Methodology 897.7 Secondary Research 907.8 Therapeutic Landscape 907.9 Epidemiology-Based Forecasting 917.10 Market Size by Geography 927.11 Pipeline Analysis 937.12 Contact Us 937.13 Disclaimer 93

## 1.1 List of Tables

Table 1: McDonald Criteria, Multiple Sclerosis, 2013 12  
Table 2: Expanded Disability Status Scale, Multiple Sclerosis, 2013 14  
Table 3: Multiple Sclerosis, Global, Market Forecast, (\$bn), 2012–2019 81  
Table 4: Multiple Sclerosis, US, Market Forecast, (\$bn), 2012–2019 81  
Table 5: Multiple Sclerosis, UK, Market Forecast, (\$bn), 2012–2019 82  
Table 6: Multiple Sclerosis, France, Market Forecast, (\$bn), 2012–2019 82  
Table 7: Multiple Sclerosis, Germany, Market Forecast, (\$bn), 2012–2019 83  
Table 8: Multiple Sclerosis, Italy, Market Forecast, (\$bn), 2012–2019 83  
Table 9: Multiple Sclerosis, Spain, Market Forecast, (\$bn), 2012–2019 84  
Table 10: Multiple Sclerosis, Japan, Market Forecast, (\$bn), 2012–2019 84

## 1.2 List of Figures

Figure 1: Treatment Algorithm, Global, Multiple Sclerosis, 2013 18  
Figure 2: Multiple Sclerosis, Marketed Products Heat Map 27  
Figure 3: Overall Pipeline for Multiple Sclerosis 30  
Figure 4: Routes of Administration in the Pipeline 31  
Figure 5: Molecular Targets of Pipeline Molecules 32  
Figure 6: Molecular Targets in MS Pipeline by Phase of Development 33  
Figure 7: Failure Rate of MS Clinical Trials, 2006–2013 35  
Figure 8: Reasons for Clinical Trial Failure, 2006–2013 36  
Figure 9: Clinical Trial Size by Product and Phase, 2006–2013 37  
Figure 10: Clinical Trial Duration by Phase and Molecule Type, 2006–2013 39  
Figure 11: Multiple Sclerosis, Pipeline Product Heat Map 45  
Figure 12: Multiple Sclerosis, Marketed Product Heat Map, 2012–2019 46  
Figure 13: Multiple Sclerosis Market, Global, Patient Volumes ('000) and Market Size (\$bn), 2012–2019 49  
Figure 14: Multiple Sclerosis Market, US, Patient Volumes ('000), Annual Cost of Treatment (\$) and Market Size (\$bn), 2012–2019 51  
Figure 15: Multiple Sclerosis Market, EU5, Patient Population ('000), 2012–2019 53  
Figure 16: Multiple Sclerosis Market, EU5, Annual Cost of Treatment (\$), 2012–2019 54  
Figure 17: Multiple Sclerosis Market, EU5, Market Size (\$bn), 2013–2019 55  
Figure 18: Multiple Sclerosis Market, Japan, Patient Volume ('000), Annual Cost of Treatment (\$) and Market Size (\$bn), 2013–2019 57  
Figure 19: Multiple Sclerosis, Co-development Deals by Geography, Value and Year, 2006–2013 61  
Figure 20: Multiple Sclerosis, Co-Development Deal Frequency by Phase and Molecule Type 2006–2013 62  
Figure 21: Multiple Sclerosis, Licensing Deals by Geography, Value and Year, 2006–2013 66  
Figure 22: Multiple Sclerosis, Licensing Deal frequency by Phase and Molecule Type, 2006–2013 67  
Figure 23: Multiple Sclerosis, Licensing Deal Value by Molecule Type and Mechanism of Action, 2006–2013 68  
Figure 24: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Discovery)

71 Figure 25: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Pre-Clinical)-I 72 Figure 26: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Pre-Clinical)-II 73 Figure 27: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Pre-Clinical)-III 74 Figure 28: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Phase I) -I 75 Figure 29: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Phase I) -II 76 Figure 30: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Phase II) - I 77 Figure 31: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Phase II) - II 78 Figure 32: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Phase III) 79 Figure 33: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Pre-Registration) 79 Figure 34: Multiple Sclerosis, Global, Pharmaceutical Pipeline (Undisclosed) 80 Figure 35: Multiple Sclerosis Market, Global, GBI Research Market Sizing Model 92

## Companies Mentioned

Teva Pharmaceuticals Bayer AG Biogen Merck Serono Biogen Idec Elan Corporation Mitsubishi Tanabe Novartis Genzyme Corporation Sanofi-Aventis Merck Serono

To order this report: [Multiple Sclerosis Therapeutics to 2019 - Treatment Diversification, Increasing Efficacy, and Pipeline Innovation Combine to Drive Growth](http://www.reportlinker.com/p01623519/Multiple-Sclerosis-Therapeutics-to-2019---Treatment-Diversification-Increasing-Efficacy-and-Pipeline-Innovation-Combine-to-Drive-Growth.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology)  
[http://www.reportlinker.com/p01623519/Multiple-Sclerosis-Therapeutics-to-2019---Treatment-Diversification-Increasing-Efficacy-and-Pipeline-Innovation-Combine-to-Drive-Growth.html#utm\\_source=prnewswire&utm\\_medium=pr&utm\\_campaign=Pathology](http://www.reportlinker.com/p01623519/Multiple-Sclerosis-Therapeutics-to-2019---Treatment-Diversification-Increasing-Efficacy-and-Pipeline-Innovation-Combine-to-Drive-Growth.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology)

Contact Clare: [clare@reportlinker.com](mailto:clare@reportlinker.com) US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

RELATED LINKS <http://www.reportlinker.com>